25Q1 环比改善，看好全年业绩修复 ——乐普医疗 2024 年报&2025 年一季报点评 核心观点 盈利预测与投资建议 伍云飞 wuyunfei1@orientsec.com.cn 执业证书编号：S0860524020001 香港证监会牌照：BRX199 ⚫ 根据 24 年报及 25 年一季报，我们下调收入及毛利率预测，我们预测公司 2025-2027 年 EPS 分别为 0.54/0.61/0.67 元（原预测 25-26 年 EPS 为 0.75、0.90 元）。根据可 比公司 2025 年平均估值，给予公司 2025 年 23 倍市盈率，对应目标价为 12.42 元， 维持给予"买入"评级。 风险提示 ⚫ 研发进展和新产品商业化不及预期；集采或者市场竞争加剧带来的冲击；大额计提 减值风险。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 7,980 | 6,103 | 6,835 | 7,378 | 7,968 | | 同比增长 (%) | ...

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 23.25 [3][7] Core Views - The company reported a revenue of CNY 36.22 billion for 2024, representing a year-on-year growth of 9%. However, the net profit attributable to the parent company decreased by 41% to CNY 1.15 billion, while the core net profit fell by 5% to CNY 2.23 billion [2][3][7] - The company's cyclical business showed steady growth, with a revenue of CNY 30.79 billion from cyclical operations, marking a 16% increase year-on-year, which now constitutes 85% of total revenue [7] - The report highlights a significant decline in the gross margin of developer-related businesses, which has dropped to 0%, indicating a potential bottoming out of core net profit [7] Financial Summary - For 2024, the company achieved a revenue of CNY 36.22 billion, with a year-on-year growth of 9.2%. The operating profit was CNY 1.70 billion, down 36.2% from the previous year. The net profit attributable to the parent company was CNY 1.15 billion, a decrease of 41.2% [4][9] - The earnings per share (EPS) for 2024 is projected at CNY 0.98, with future estimates of CNY 1.54, CNY 1.90, and CNY 2.10 for 2025, 2026, and 2027 respectively [4][9] - The gross margin is expected to decline to 13% in 2024, with a slight recovery projected in subsequent years [4][9] Business Segments - The community space, commercial city services, and technology segments generated revenues of CNY 20.9 billion, CNY 12.3 billion, and CNY 3.0 billion respectively, with year-on-year growth rates of 11.5%, 5.4%, and 8.6% [7] - The company has successfully reduced its reliance on related party transactions, with the proportion of revenue from related parties decreasing by 4 percentage points to 9.5% [7] Market Comparison - The report provides a comparison of the company's valuation metrics against peers, indicating an adjusted average PE of 14x for comparable companies in 2025 [3][8]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.77 CNY based on a 69 times price-to-earnings ratio for 2025 [2][5]. Core Views - The company's performance is under short-term pressure but is expected to grow in the medium to long term. The revenue forecast for 2025-2027 has been adjusted, with earnings per share projected at 0.33, 0.61, and 1.01 CNY respectively [1][2]. - The company reported a revenue of 721 million CNY for 2024, a decrease of 5.2% year-on-year, and a net profit of 108 million CNY, down 32.4% year-on-year. The first quarter of 2025 saw a revenue of 185 million CNY, a decline of 2.35% [9]. - The company is facing increased competition in the two-sex health sector, leading to a 20.87% decline in revenue from this segment. However, there is significant growth potential in the gastrointestinal medication market, with new product registrations expected to boost revenue [9]. Financial Summary - The company's financial performance shows a projected revenue increase from 721 million CNY in 2024 to 1.52 billion CNY in 2027, reflecting a compound annual growth rate of 31.9% [4][11]. - The gross margin is expected to improve from 56.7% in 2024 to 71.7% in 2027, while the net profit margin is projected to rise from 15.0% to 28.2% over the same period [4][11]. - The company's earnings per share are forecasted to increase from 0.25 CNY in 2024 to 1.01 CNY in 2027, indicating strong growth potential [4][11].

业绩环比修复，海内外市场同步拓展 ——海泰新光 2024 年报&2025 年一季报点评 风险提示 大客户依赖风险、地缘政治风险、国内市场拓展不及预期风险、下游需求波动风险 等。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 471 | 443 | 565 | 691 | 868 | | 同比增长 (%) | -1.3% | -5.9% | 27.5% | 22.4% | 25.6% | | 营业利润(百万元) | 161 | 153 | 206 | 241 | 302 | | 同比增长 (%) | -22.0% | -5.0% | 34.7% | 17.2% | 25.3% | | 归属母公司净利润(百万元) | 146 | 135 | 183 | 216 | 269 | | 同比增长 (%) | -20.2% | -7.1% | 34.9% | 18.1% | 24.8% | | 每股收益（元） | 1.21 | 1.12 | 1.51 | 1. ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.77 CNY based on a 69 times price-to-earnings ratio for 2025 [2][5]. Core Views - The company is experiencing short-term performance pressure but is expected to achieve long-term growth. The revenue forecast for 2025-2027 has been adjusted, with earnings per share projected at 0.33 CNY, 0.61 CNY, and 1.01 CNY respectively [1][2]. - The company reported a revenue of 721 million CNY for 2024, a decrease of 5.2% year-on-year, and a net profit of 108 million CNY, down 32.4% year-on-year. The first quarter of 2025 saw a revenue of 185 million CNY, a decline of 2.35% [9]. - The company is focusing on enhancing its product offerings and marketing strategies, particularly in the gastrointestinal and sexual health segments, while also making progress in R&D for new drugs [9]. Financial Summary - The company's financial performance shows a decline in revenue and net profit for 2024, with a projected recovery starting in 2025. The revenue is expected to grow by 24.0% in 2025, followed by 28.8% in 2026 and 31.9% in 2027 [4][11]. - Key financial metrics include: - Revenue (2023A: 761 million CNY, 2024A: 721 million CNY, 2025E: 894 million CNY) - Net profit (2023A: 160 million CNY, 2024A: 108 million CNY, 2025E: 140 million CNY) - Earnings per share (2023A: 0.38 CNY, 2024A: 0.25 CNY, 2025E: 0.33 CNY) [4][11].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.77 CNY based on a 69 times price-to-earnings ratio for 2025 [2][5]. Core Views - The company's performance is under short-term pressure but is expected to grow in the medium to long term. The revenue forecast for 2025-2027 has been adjusted, with earnings per share projected at 0.33 CNY, 0.61 CNY, and 1.01 CNY respectively [2][9]. - The company reported a revenue of 721 million CNY for 2024, a decrease of 5.2% year-on-year, and a net profit of 108 million CNY, down 32.4% year-on-year. The first quarter of 2025 saw a revenue of 185 million CNY, a decline of 2.35% [4][9]. - The company is facing increased competition in the two-sex health sector, leading to a 20.87% decline in revenue from this segment. However, there is significant growth potential in the gastrointestinal medication market, with new product registrations expected to boost revenue [9]. Financial Summary - The company’s revenue is projected to grow from 721 million CNY in 2024 to 1.52 billion CNY in 2027, reflecting a compound annual growth rate of 31.9% [4][11]. - The gross margin is expected to improve from 56.7% in 2024 to 71.7% in 2027, while the net profit margin is projected to increase from 15.0% to 28.2% over the same period [4][11]. - The company’s net profit is forecasted to rise from 108 million CNY in 2024 to 428 million CNY in 2027, indicating a strong recovery and growth trajectory [4][11].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 47.79 CNY, based on a 27x PE for 2025 [2][4]. Core Views - The company reported Q1 2025 revenue of 4.839 billion CNY, a year-on-year increase of 20.56%, but a net profit attributable to shareholders of 640 million CNY, down 14.78% [1][8]. - The decline in profitability is attributed to a lower proportion of military products, changes in product structure, and rising raw material costs, leading to a gross margin decrease to 28.44% (down 7.12 percentage points) and a net margin decrease to 13.91% (down 5.88 percentage points) [8]. - The company plans to repurchase shares worth between 150 million and 300 million CNY, representing 0.14%-0.28% of the total shares, to enhance investor confidence and internal motivation [8]. - The defense sector is expected to recover, and new industries such as civil aviation and satellite internet present growth opportunities, indicating potential for a return to high-quality growth [8]. Financial Information Summary - Revenue projections for 2025-2027 are 23.778 billion CNY, 27.536 billion CNY, and 31.978 billion CNY, respectively, with expected growth rates of 14.9%, 15.8%, and 16.1% [3]. - The net profit attributable to shareholders is projected to grow from 3.740 billion CNY in 2025 to 5.101 billion CNY in 2027, with growth rates of 11.5% and 17.5% [3]. - The company’s gross margin is expected to stabilize around 36.2% from 2025 to 2027, while the net margin is projected to be around 15.7% to 16.0% [3].

Investment Rating - The investment rating for Jiangsu Bank is "Buy (Maintain)" [8] Core Views - The core revenue has significantly improved, with a decrease in the non-performing loan ratio on a quarter-on-quarter basis [2] - The bank's performance growth has exceeded expectations, with notable improvements in net interest income and fee income growth [8] - The bank's total assets and loan amounts have shown strong growth, indicating a favorable lending environment [8] - The asset quality is stabilizing, with a slight decrease in the non-performing loan ratio and a robust provision coverage ratio [8] Financial Performance Summary - For 2023A, the operating income is projected at 74,293 million yuan, with a year-on-year growth of 5.3% [4] - The net profit attributable to the parent company is expected to reach 28,750 million yuan in 2023A, reflecting a year-on-year increase of 13.3% [4] - The earnings per share (EPS) for 2023A is estimated at 1.52 yuan [4] - The bank's total assets are projected to grow to 4,235,199 million yuan by 2025E, with a loan growth rate of 14% [10] Valuation Metrics - The target price for Jiangsu Bank is set at 12.62 yuan per share, with a current price of 10.13 yuan [5] - The price-to-earnings (P/E) ratio for 2025E is projected at 5.67, while the price-to-book (P/B) ratio is expected to be 0.72 [8][10] - The bank's average return on equity (ROE) is forecasted to be 13.31% in 2025E [10]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 245.86 CNY for 2025, based on a 19x PE ratio [4][10]. Core Insights - The company reported a revenue of 23.58 billion CNY for 2024, representing a year-on-year growth of 16.4%, and a net profit attributable to the parent company of 5.52 billion CNY, up 20.2% year-on-year [9]. - The core driver of revenue growth is the "Year Original" series, which generated 18.09 billion CNY in revenue, with sales volume and price per ton increasing by 12% and 5% respectively [9]. - The company has seen a solid performance in its main market, with revenue from the Central China region reaching 20.15 billion CNY, a growth of 17.8% year-on-year [9]. Financial Summary - The company’s financial projections for 2025-2027 indicate an EPS of 12.94 CNY, 15.16 CNY, and 17.43 CNY respectively, with a downward adjustment from previous estimates [10]. - The gross margin for 2024 is projected to be 79.9%, with a slight increase from the previous year, driven by product mix upgrades [9]. - The net profit margin is expected to improve to 25.0% by 2025, reflecting ongoing enhancements in profitability [3][9]. Revenue and Profit Forecast - The company anticipates revenues of 27.36 billion CNY in 2025, 31.15 billion CNY in 2026, and 35.03 billion CNY in 2027, with respective growth rates of 16.0%, 13.8%, and 12.5% [3]. - Operating profit is projected to reach 9.38 billion CNY in 2025, with a year-on-year growth of 21.0% [3]. Market Position and Strategy - The company has expanded its distributor network to 5,089, with a notable increase in Central China, indicating a strategy focused on regional market penetration [9]. - The product structure continues to upgrade, with a significant contribution from mid-to-high-end products, enhancing overall profitability [9].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 40.32 CNY [2][6]. Core Insights - The company is experiencing improved gross margins and is accelerating its expansion into new product areas, particularly in the electric vehicle sector [1][10]. - The first quarter of 2025 showed a revenue of 6.62 million CNY, a year-on-year increase of 29.7%, and a net profit attributable to the parent company of 0.48 million CNY, up 13.8% year-on-year [10]. - The company is actively developing new products in the new energy sector and has successfully completed a fundraising project to support its smart manufacturing initiatives [10]. Financial Forecast and Performance - The forecasted net profit attributable to the parent company for 2025, 2026, and 2027 is expected to be 244 million CNY, 305 million CNY, and 375 million CNY respectively, with a significant growth rate of 49.1% in 2025 [2][4]. - Revenue is projected to grow from 2,020 million CNY in 2023 to 4,032 million CNY in 2027, reflecting a compound annual growth rate (CAGR) of 18.5% [4][11]. - The gross margin is expected to improve from 21.8% in 2023 to 25.7% in 2027, indicating enhanced profitability [4][11]. Strategic Initiatives - The company is expanding its client base in the new energy vehicle sector, targeting major clients such as Bosch and NIO, and plans to increase production capacity significantly [10]. - A joint venture has been established to enhance the company's capabilities in the robotics sector, focusing on humanoid robots and automotive electronic components [10].